Role of cardiovascular magnetic resonance in acute and chronic ischemic heart disease (2024)

1. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–2619. doi:10.1093/eurheartj/ehs215. [PubMed] [CrossRef] [Google Scholar]

2. Abdel-Aty H, Simonetti O, Friedrich MG. T2-weighted cardiovascular magnetic resonance imaging. J Magn Reson Imaging. 2007;26:452–459. doi:10.1002/jmri.21028. [PubMed] [CrossRef] [Google Scholar]

3. Ridgway JP. Cardiovascular magnetic resonance physics for clinicians: part I. J Cardiovasc Magn Reson. 2010;12(1):71. doi:10.1186/1532-429X-12-71. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Biglands JD, Radjenovic A, Ridgway JP. Cardiovascular magnetic resonance physics for clinicians: part II. J Cardiovasc Magn Reson. 2012;14(1):66. doi:10.1186/1532-429X-14-66. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Eitel I, Friedrich MG. T2-weighted cardiovascular magnetic resonance in acute cardiac disease. J Cardiovasc Magn Reson. 2011;13(1):13. doi:10.1186/1532-429X-13-13. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Francone M, Bucciarelli-Ducci C, Carbone I, et al. Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight fro cardiovascular magnetic resonance. JACC. 2009;54(23):2145–2153. doi:10.1016/j.jacc.2009.08.024. [PubMed] [CrossRef] [Google Scholar]

7. Aletras AH, Tilak GS, Natanzon A, et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation. 2006;113(15):1865–1870. doi:10.1161/CIRCULATIONAHA.105.576025. [PubMed] [CrossRef] [Google Scholar]

8. Desch S, Eitel I, de Waha S, et al. Cardiac magnetic resonance imaging parameters as surrogate endpoints in clinical trials of acute myocardial infarction. Trials. 2011;12(1):204. doi:10.1186/1745-6215-12-204. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Rajiah P, Deasi MY, Kwon D, Flamm SD. MR imaging of myocardial infarction. Radiographics. 2013;33:1383–1412. doi:10.1148/rg.335125722. [PubMed] [CrossRef] [Google Scholar]

10. Kerensky RA, Wade M, Deedwania P, et al. Revisiting the culprit lesion in non–Q-wave myocardial infarction: results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol. 2002;39(9):1456–1463. doi:10.1016/S0735-1097(02)01770-9. [PubMed] [CrossRef] [Google Scholar]

11. Monney PA, Sekhri N, Burchell T, et al. Acute myocarditis presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis. Heart. 2011;97(16):1312–1319. doi:10.1136/hrt.2010.204818. [PubMed] [CrossRef] [Google Scholar]

12. Gallagher S, Jones DA, Anand V, Mohiddin S. Diagnosis and management of patients with acute cardiac symptoms, troponin elevation and culprit-free angiograms. Heart. 2012;98(13):974–982. doi:10.1136/heartjnl-2011-301121. [PubMed] [CrossRef] [Google Scholar]

13. Raman SV, Simonetti OP, Winner MW, et al. Cardiac magnetic resonance with edema imaging identifies myocardium at risk and predicts worse outcome in patients with non–ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010;55(22):2480–2488. doi:10.1016/j.jacc.2010.01.047. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Walls MC, Verhaert D, Raman SV. Myocardial edema imaging in acute coronary syndromes. J Magn Reson Imaging. 2011;34(6):1243–1250. doi:10.1002/jmri.22737. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Basso C, Thiene G. The pathophysiology of myocardial reperfusion: a pathologist’s perspective. Heart. 2006;92(11):1559–1562. doi:10.1136/hrt.2005.086959. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Hunold P, Bischoff P, Barkhausen J, Vogt FM. Acute chest pain: the role of MR imaging and MR angiography. Eur J Radiol. 2012;81(12):3680–3690. doi:10.1016/j.ejrad.2011.04.032. [PubMed] [CrossRef] [Google Scholar]

17. Rochitte CE, Lima AC, Bluemke DA, et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation. 1998;98(10):1006–1015. doi:10.1161/01.CIR.98.10.1006. [PubMed] [CrossRef] [Google Scholar]

18. Beek AM, van Rossum AC. Cardiovascular magnetic resonance imaging in patients with acute myocardial infarction. Heart. 2010;96:237–243. doi:10.1136/hrt.2009.172296. [PubMed] [CrossRef] [Google Scholar]

19. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97(8):765–772. doi:10.1161/01.CIR.97.8.765. [PubMed] [CrossRef] [Google Scholar]

20. Flavian A, Carta F, Thuny F, et al. Cardiac MRI in the diagnosis of complications of myocardial infarction. Diagn Interv Imaging. 2012;93(7–8):578–585. doi:10.1016/j.diii.2012.05.012. [PubMed] [CrossRef] [Google Scholar]

21. Eitel I, de Waha, Wöhrle J, et al. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014;64(12):1217–1226. doi:10.1016/j.jacc.2014.06.1194. [PubMed] [CrossRef] [Google Scholar]

22. Hombach V, Grebe O, Merkle N, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J. 2005;26(6):549–557. doi:10.1093/eurheartj/ehi147. [PubMed] [CrossRef] [Google Scholar]

23. de Waha S, Desch S, Eitel I, et al. Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction: a comparison with traditional prognostic markers. Eur Heart J. 2010;31(21):2660–2668. doi:10.1093/eurheartj/ehq247. [PubMed] [CrossRef] [Google Scholar]

24. de Waha S, Desch S, Eitel I, et al. Relationship and prognostic value of microvascular obstruction and infarct size in ST-elevation myocardial infarction as visualized by magnetic resonance imaging. Clin Res Cardiol. 2012;101(6):487–495. doi:10.1007/s00392-012-0419-3. [PubMed] [CrossRef] [Google Scholar]

25. Eitel I, Kubusch K, Strohm O, et al. Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevationmyocardial infarction. Circ Cardiovasc Imaging. 2011;4(4):354–363. doi:10.1161/CIRCIMAGING.110.960500. [PubMed] [CrossRef] [Google Scholar]

See Also

What’s Draggin’ Your Heart Down?

51. Karamitsos TD, Dall’Armellina E, Choudhury RP, Neubauer S. Ischemic heart disease: comprehensive evaluation by cardiovascular magnetic resonance. Am Heart J. 2011;162(1):16–30. doi:10.1016/j.ahj.2011.04.011. [PubMed] [CrossRef] [Google Scholar]

52. Ibrahim T, Bülow HP, Hackl T, et al. Diagnostic value of contrast-enhanced magnetic resonance imaging and single-photon emission computed tomography for detection of myocardial necrosis early after acute myocardial infarction. J Am Coll Cardiol. 2007;49(2):208–216. doi:10.1016/j.jacc.2006.08.047. [PubMed] [CrossRef] [Google Scholar]

53. Ganame J, Messalli G, Masci PG, et al. Time course of infarct healing and left ventricular remodelling in patients with reperfused ST segment elevation myocardial infarction using comprehensive magnetic resonance imaging. Eur Radiol. 2011;21(4):693–701. doi:10.1007/s00330-010-1963-8. [PubMed] [CrossRef] [Google Scholar]

54. Masci PG, Bogaert J. Post myocardial infarction of the left ventricle: the course ahead seen by cardiac MRI. Cardiovasc Diagn Ther. 2012;2(2):113–127. [PMC free article] [PubMed] [Google Scholar]

55. Orn S, Manhenke C, Anand IS, et al. Effect of left ventricular size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. Am J Cardiol. 2007;99(8):1109–1114. doi:10.1016/j.amjcard.2006.11.059. [PubMed] [CrossRef] [Google Scholar]

56. Grover S, Bell G, Lincoff M, et al. Utility of CMR markers of myocardial injury in predicting LV functional recovery: results from PROTECTION AMI CMR Sub-study. Heart Lung Circ. 2015;24(9):891–897. doi:10.1016/j.hlc.2015.03.001. [PubMed] [CrossRef] [Google Scholar]

57. Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation and assessment of myocardial viability. Circulation. 2008;117:103–114. doi:10.1161/CIRCULATIONAHA.107.702993. [PubMed] [CrossRef] [Google Scholar]

58. Birnbaum Y, Kloner RA. Myocardial viability. West J Med. 1996;165(6):364–371. [PMC free article] [PubMed] [Google Scholar]

59. Gerber BL, Rousseau MF, Ahn SA, et al. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction impact of revascularization therapy. J Am Coll Cardiol. 2012;59(9):825–835. doi:10.1016/j.jacc.2011.09.073. [PubMed] [CrossRef] [Google Scholar]

60. Kaandorp TAM, Lamb HJ, van der Wall EE, de Roos A, Bax JJ. Cardiovascular MR to assess myocardial viability in chronic ischaemic LV dysfunction. Heart. 2005;91:1359–1365. doi:10.1136/hrt.2003.025353. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

61. Jerosh-Herold M, Kwong RJ. Magnetic resonance imaging in the assessment of ventricular remodeling and viability. Curr Heart Fail Rep. 2008;5(1):5–10. doi:10.1007/s11897-008-0002-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

62. Kitagawa K, Sakuma H, Hirano T, et al. Acute myocardial infarction: myocardial viability assessment in patients early thereafter—comparison of contrast-enhanced MR imaging with resting (201)Tl SPECT: single photon emission computed tomography. Radiology. 2003;226(1):138–144. doi:10.1148/radiol.2261012108. [PubMed] [CrossRef] [Google Scholar]

63. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445–1453. doi:10.1056/NEJM200011163432003. [PubMed] [CrossRef] [Google Scholar]

64. Selvanayagam JB, Kardos A, Francis JM, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004;110:1535–1541. doi:10.1161/01.CIR.0000142045.22628.74. [PubMed] [CrossRef] [Google Scholar]

65. Pegg TJ, Selvanayagam JB, Jennifer J, et al. Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12(1):56. doi:10.1186/1532-429X-12-56. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

66. Baer FM, Voth E, Schneidr CA, et al. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F] fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation. 1995;91:1006–1015. doi:10.1161/01.CIR.91.4.1006. [PubMed] [CrossRef] [Google Scholar]

67. Shah DJ, Kim HW, James O, et al. Prevalence of regional myocardial thinning and relationship with myocardial scarring in patients with coronary artery disease. JAMA. 2013;309(9):909–918. doi:10.1001/jama.2013.1381. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

68. Larose E, Rodes-Cabau J, Pibarot P, et al. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction and necrosis characteristics by cardiovascular magnetic resonance. J Am Coll Cardiol. 2010;55(22):2459–2469. doi:10.1016/j.jacc.2010.02.033. [PubMed] [CrossRef] [Google Scholar]

69. Izquierdo M, Ruiz-Granell R, Bonanad C, et al. Value of early cardiovascular magnetic resonance for the prediction of adverse arrhythmic cardiac events after a first noncomplicated ST-segment-elevation myocardial infarction. Circ Cardiovasc Imaging. 2013;6(5):755–761. doi:10.1161/CIRCIMAGING.113.000702. [PubMed] [CrossRef] [Google Scholar]

70. Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008;94(6):730–737. doi:10.1136/hrt.2007.122622. [PubMed] [CrossRef] [Google Scholar]

71. Abbasi SA, Ertel A, Shah RV, et al. Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients. J Cardiovasc Magn Reson. 2013;15(1):89. doi:10.1186/1532-429X-15-89. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

72. Catalano O, Moro G, Perotti M, et al. Late gadolinium enhancement by cardiovascular magnetic resonance is complementary to left ventricle ejection fraction in predicting prognosis of patients with stable coronary artery disease. J Cardiovasc Magn Reson. 2012;14:29. doi:10.1186/1532-429X-14-29. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

73. Scott PA, Rosengarten JA, Curzen NP, Morgan JM. Late gadolinium enhancement cardiac magnetic resonance imaging for the prediction of ventricular tachyarrhythmic events: a meta-analysis. Eur J Heart Fail. 2013;15:1019–1027. doi:10.1093/eurjhf/hft053. [PubMed] [CrossRef] [Google Scholar]

74. Boyé P, Abdel-Aty H, Zacharzowsky U, et al. Prediction of life-threatening arrhythmic events in patients with chronic myocardial infarction by contrast-enhanced CMR. JACC Cardiovasc Imaging. 2011;4(8):871–879. doi:10.1016/j.jcmg.2011.04.014. [PubMed] [CrossRef] [Google Scholar]

75. Arenal A, Hernandez J, Perez-David E, et al. Do the spatial characteristics of myocardial scar tissue determine the risk of ventricular arrhythmias? Cardiovasc Res. 2012;94(2):324–332. doi:10.1093/cvr/cvs113. [PubMed] [CrossRef] [Google Scholar]

76. Rijnierse MT, Allaart CP, de Haan S, et al. Non-invasive imaging to identify susceptibility for ventricular arrhythmias in ischaemic left ventricular dysfunction. J Am Coll Cardiol. 2016;67(13_S):1818. doi:10.1016/S0735-1097(16)31819-8. [PubMed] [CrossRef] [Google Scholar]

77. Yalin K, Golcuk E, Buyukbayrak H, et al. Infarct characteristics by CMR identifies substrate for monomorphic VT in post-MI patients with relatively preserved systolic function and ns-VT. PACE. 2014;37(4):447–453. doi:10.1111/pace.12289. [PubMed] [CrossRef] [Google Scholar]

78. Flett AS, Hasleton J, Cook C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4(2):150–156. doi:10.1016/j.jcmg.2010.11.015. [PubMed] [CrossRef] [Google Scholar]

79. Schmidt A, Azevedo CF, Cheng A, et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation. 2007;115(15):2006–2014. doi:10.1161/CIRCULATIONAHA.106.653568. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

80. Estner HL, Zviman MM, Herzka D, et al. The critical isthmus sites of ischemic ventricular tachycardia are in zones of tissue heterogeneity, visualized by magnetic resonance imaging. Heart Rhythm. 2011;8(12):1942–1949. doi:10.1016/j.hrthm.2011.07.027. [PubMed] [CrossRef] [Google Scholar]

81. White JA, Yee R, Yuan X, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol. 2006;48(10):0–7. doi:10.1016/j.jacc.2006.07.046. [PubMed] [CrossRef] [Google Scholar]

82. Chalil S, Foley PW, Muyhaldeen SA, et al. Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace. 2007;9(11):1031–1037. doi:10.1093/europace/eum133. [PubMed] [CrossRef] [Google Scholar]

83. Brignole M, Auricchio A, Baron-Esquivias G, et al. ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association. Eur Heart J. 2013;34(29):2281–2329. doi:10.1093/eurheartj/eht150. [PubMed] [CrossRef] [Google Scholar]

84. Pennell DJ. Ventricular volume and mass by CMR. J Cardiovasc Magn Reson. 2002;4(4):507–513. doi:10.1081/JCMR-120016389. [PubMed] [CrossRef] [Google Scholar]

85. Pennell DJ. Cardiovascular magnetic resonance. Circulation. 2010;121(5):692–705. doi:10.1161/CIRCULATIONAHA.108.811547. [PubMed] [CrossRef] [Google Scholar]

86. Bettencourt N, Chiribiri A, Schuster A, Nagel E. Assessment of myocardial ischemia and viability using cardiac magnetic resonance. Curr Heart Failr Rep. 2009;6(3):142–153. doi:10.1007/s11897-009-0021-9. [PubMed] [CrossRef] [Google Scholar]

87. Schwitter J, Wacker CM, Van Rossum AC, et al. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J. 2008;29(4):480–489. doi:10.1093/eurheartj/ehm617. [PubMed] [CrossRef] [Google Scholar]

88. Desai RR, Jha S. Diagnostic performance of cardiac stress perfusion MRI in the detection of coronary artery disease using fractional flow reserve as teh refernec standard: a meta-analysis. Am J Roentgenol. 2013;201(2):245–252. doi:10.2214/AJR.12.10002. [PubMed] [CrossRef] [Google Scholar]

89. Nandalur KR, Dwamena BA, Choudhri AF, Nadalur MR, Carlos RC. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2007;50(14):1343–1353. doi:10.1016/j.jacc.2007.06.030. [PubMed] [CrossRef] [Google Scholar]

90. Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic resonance and single-photon emission compute tomography for diagnosis of coronary artery disease (CE-MARC): a prospective trial. Lancet. 2012;379:453–460. doi:10.1016/S0140-6736(11)61335-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

91. Schwitter J, Nanz D, Kneifel S, et al. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance. A comparison with positron emission tomography and coronary angiography. Circulation. 2001;103:2230–2235. doi:10.1161/01.CIR.103.18.2230. [PubMed] [CrossRef] [Google Scholar]

92. Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI. Comparison with dobutamine stress echocardiography. Circulation. 1999;99:763–770. doi:10.1161/01.CIR.99.6.763. [PubMed] [CrossRef] [Google Scholar]

93. Schneeweis C, Qiu J, Schnackenburg B, et al. Value of additional strain analysis with feature tracking in dobutamine stress cardiovascular magnetic resonance for detecting coronary artery disease. J cardiovasc Magn Reson. 2014;16:72. doi:10.1186/s12968-014-0072-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

94. Ingkanisorn WP, Kwong RY, Bohme NS, et al. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. J Am Coll Cardiol. 2006;47:1427–1432. doi:10.1016/j.jacc.2005.11.059. [PubMed] [CrossRef] [Google Scholar]

95. Jahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac magnetic resonance stress test. Adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation. 2007;115:1769–1776. doi:10.1161/CIRCULATIONAHA.106.652016. [PubMed] [CrossRef] [Google Scholar]

96. Sozzi FB, Iacuzio L, Civaia F, et al. I Incremental value of normal adenosine perfusion cardiac magnetic resonance: long-term outcome. Am Heart J. 2015;169(6):841–846. doi:10.1016/j.ahj.2015.03.001. [PubMed] [CrossRef] [Google Scholar]

97. Kelle S, Chiribiri A, Vierecke J, et al. Long-term prognostic value of stress CMR. JACC Cardiovasc Imaging. 2011;4(2):161–172. doi:10.1016/j.jcmg.2010.11.012. [PubMed] [CrossRef] [Google Scholar]

98. Lipinski MJ, McVey CM, Berger JS, et al. Prognostic value of stress cardiac magnetic resonance imaging in patients with known or suspected coronary artery disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62(9):826–838. doi:10.1016/j.jacc.2013.03.080. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

99. Windecker S, Kohl P, Alfonso F, et al. ESC/EACTS guidelines on myocardial revascularization the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association. Eur Heart J. 2014;35:2541–2619. doi:10.1093/eurheartj/ehu278. [PubMed] [CrossRef] [Google Scholar]

100. Greenwood JP, Herzog BA, Brown JM, et al. Prognostic value of cardiovascular magnetic resonance and single-photon emission computed tomography in suspected coronary heart disease: long-term follow-up of a prospective, diagnostic accuracy cohort study. Ann Intern Med. 2016;165:1–9. doi:10.7326/M15-1801. [PubMed] [CrossRef] [Google Scholar]

101. Montalescot G, Sechtem U, Achenbach S, et al. ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. doi:10.1093/eurheartj/eht296. [PubMed] [CrossRef] [Google Scholar]

FAQs

Role of cardiovascular magnetic resonance in acute and chronic ischemic heart disease? ›

Due to its ability to identify myocardial fibrosis, CMR has had its widest application in the assessment of chronic ischemic heart disease (IHD) [46, 47]. Detection of fibrosis is based on the analysis of the distribution of the contrast agent within the myocardium, 10–15 min after its administration.

Know More ›

What is the role of cardiovascular magnetic resonance in acute and chronic ischemic heart disease? ›

Cardiac magnetic resonance (CMR) imaging is a valuable, non-invasive diagnostic tool that can aide clinicians to build a differential diagnosis in patients with MINOCA, as well as identifying non-ischemic etiologies of myocardial injury (acute myocarditis, Takotsubo Syndrome, and other conditions).

See Details ›

What is the role of cardiovascular magnetic resonance? ›

Based on its accuracy in assessing LV volume and MR severity, and predicting LV reverse remodelling after correction, CMR should be employed not only to confirm the severity and help guide surgical decision-making but also to quantitatively assess the severity of MR in patients with equivocal findings on ...

Discover More Details ›

What is the role of MRI in ischemic heart disease? ›

Late gadolinium enhancement by MRI has the unique feature to demonstrate the transmural extent of scar. Transmural extent of scar is very important for diagnosis of remaining myocardial viability and therefore for clinical decision-making in patients with ischemic heart disease.

Get More Info ›

What is the role of cardiovascular MRI in heart failure and the cardiomyopathies? ›

Cardiac MRI has long been a gold standard measure of myocardial function and anatomy due to its high spatial and temporal resolution. More recently, it has been posited to play a more critical role in the diagnosis and prognosis of cardiomyopathy-related heart failure.

What is the role of MRI in acute ischemic stroke? ›

MRI can differentiate between brain tissue at risk for infarction and brain tissue that has been irreparably damaged. Lacunar infarcts and brainstem infarcts can be identified by MRI, whereas CT scans have difficulty due to the surrounding bone.

Tell Me More ›

What is the role of cardiovascular magnetic resonance imaging in cardio oncology? ›

Within the field of cardio-oncology, the role of CMR has not been fully defined, however CMR is suggested for individuals with poor echocardiographic windows, a borderline LVEF, or discrepant clinical values. Additionally, CMR may be particularly useful in detecting subclinical cardiovascular disease.

Know More ›

What is the purpose of an MRI of the heart? ›

Cardiac MRI helps your doctor detect or monitor cardiac disease by: evaluating the anatomy and function of the heart chambers, heart valves, size of and blood flow through major vessels, and the surrounding structures such as the pericardium (the sac that surrounds the heart).

Get More Info ›

How does ischemia look on MRI? ›

Numerous studies have shown that ADCs in ischemic areas are lower by 50% or more compared with those of normal brain areas, and they appear as bright areas (ie, hyperintensities) on DWI (see the image below). Studies have demonstrated that changes in the ADC occur as early as 10 minutes following the onset of ischemia.

Keep Reading ›

What is the imaging of the heart for ischemia? ›

Cardiac MRI is a non-invasive functional imaging method, which allows the evaluation of myocardial perfusion and viability for the assessment of myocardial ischemia.

Know More ›

What is the role of cardiovascular magnetic resonance imaging in the evaluation of hypertrophic cardiomyopathy? ›

Cardiac magnetic resonance (CMR) is a comprehensive evaluation tool capable of providing information on cardiac morphology and function, flow, perfusion, and tissue characterisation. CMR allows to detect subtle abnormalities in the myocardial composition and characterise the heterogeneous phenotypic expression of HCM.

View Details ›

What is the role of MRI in clinical cardiology? ›

MRI is used in the morphological and functional evaluation of pericardial disease. MRI can detect congenital pericardial abnormalities, such as absence, cysts and diverticula.

Know More ›

What is the role of cardiac MR imaging in cardiomyopathy? ›

CMR is the gold standard for the diagnosis of arrhythmogenic RV cardiomyopathy. Diagnostic findings in this disease include RV dilatation and global or regional dysfunction, including focal RV systolic bulging or aneurysm, and are carefully defined to meet Task Force criteria (64).

View Details ›

What is the role of Mirna in cardiovascular diseases? ›

These miRNAs are involved in mesodermal precursor differentiation, in transdifferentiation/reprogramming of adult fibroblasts/myofibroblasts into mature cardiomyocytes, and preservation of normal function and survival of cardiomyocytes.

Know More ›

What is CMR for ischemic heart disease? ›

CMR provides a comprehensive evaluation of cardiovascular disease, including evaluation of myocardial structure and function, inflammation, ischemia, and viability. CMR has advantages in chronic coronary syndromes or stable CAD compared with other methods in women.

Show Me More ›

What is the role of echocardiography in ischemic heart disease? ›

Echocardiography is an excellent tool for the diagnosis of acute, chronic and exercise-induced ischemia. The critical use of echocardiography is recommended (94).